Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Copanlisib, Olaparib, and Durvalumab in Advanced Solid Tumors
NCT03842228Phase 1Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Nov 2019
- Primary completion
- Jul 2024
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label trial of copanlisib, olaparib and durvalumab in solid tumor (2 arms), sponsored by National Cancer Institute. Primary endpoint: Dose Limiting Toxicities. Started Nov 2019; status: active, not recruiting.
02
Drugs
copanlisibolaparibdurvalumab
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03842228.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03842228.